Patient-derived xenografts as tools in pharmaceutical development.

@article{Izumchenko2016PatientderivedXA,
  title={Patient-derived xenografts as tools in pharmaceutical development.},
  author={Eugene A Izumchenko and Juliet Meir and Atul Bedi and Piotr T. Wysocki and Mohammad Obaidul Hoque and David Sidransky},
  journal={Clinical pharmacology and therapeutics},
  year={2016},
  volume={99 6},
  pages={612-21}
}
Successful drug development in oncology is grossly suboptimal, manifested by the very low percentage of new agents being developed that ultimately succeed in clinical approval. This poor success is in part due to the inability of standard cell-line xenograft models to accurately predict clinical success and to tailor chemotherapy specifically to a group of patients more likely to benefit from the therapy. Patient-derived xenografts (PDXs) maintain the histopathological architecture and… CONTINUE READING
Highly Cited
This paper has 26 citations. REVIEW CITATIONS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…